Onkologie. 2022:16(2):81-86 | DOI: 10.36290/xon.2022.016

Vaccination of cancer patients

©árka Rumlarová1, 2, Lucie Siráková2, Petr ©mahel1, 2, Josef Chmelař1, 2, Roman Chlíbek2
1 Klinika infekčních nemocí, Fakultní nemocnice a Lékařská fakulta UK v Hradci Králové
2 Fakulta vojenského zdravotnictví, Univerzity obrany v Brně

Cancer patients have an increased risk of infectious complications, the main cause of which is an immunodeficiency condition caused by the cancer itself and its therapy. Therefore, it is appropriate to protect patients by vaccination, in particular vaccination against influenza, pneumococcal infections and covid-19. Appropriately chosen vaccines and the right timing of their administration can as a part of supportive care contribute to the success of cancer therapy.

Keywords: vaccination, cancer disease, risk of infection, inactivated vaccines, live attenuated vaccines.

Published: March 25, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rumlarová ©, Siráková L, ©mahel P, Chmelař J, Chlíbek R. Vaccination of cancer patients. Onkologie. 2022;16(2):81-86. doi: 10.36290/xon.2022.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jeseňák M, Urbančíková I, et al. Očkovanie v ąpeciálnych situáciách. Praha: Mladá fronta, a. s.; 2019.
    2. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis. 2014;58:e44-100. Go to original source... Go to PubMed...
    3. Laws HJ, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz. Bundesgesundheitsbl. 2020;63:588-644. doi.org/10.1007/s00103-020-03123-w. Go to original source... Go to PubMed...
    4. Chlíbek R, et al. Očkování dospělých. Praha: Mladá fronta a. s.; 2019.
    5. Wiedermann U, Sitte H, Burgmann H, et al. Impfungen bei Immundefekten/Immunsuppression -Expertenstatement und Empfehlungen. Wien Klin Wochenschr. 2016;128 [Suppl 4]:337-376. doi 10.1007/s00508-016-1033-6. Go to original source... Go to PubMed...
    6. Kiss I, et al. Modrá kniha České onkologické společnosti, 27. aktualizace. Brno: Masarykův onkologický ústav; 2021.
    7. Doubek M, Mayer J, et al. Léčebné postupy v hematologii 2020. Doporučení České hematologické společnosti České lékařské společnosti Jana Evangelisty Purkyně. Brno: Česká hematologická společnost ČLS JEP; 2020.
    8. Kosina P, Rumlarová ©. Vakcinace u imunokompromitovaných osob. Remedia. 2014;24:363-369. Go to original source... Go to PubMed...
    9. Läubli H, Balmelli C, Kaufmann L, et al. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. J Immunother Cancer. 2018;6(1):40. doi: 10.1186/s40425-018-0353-7. Go to original source... Go to PubMed...
    10. Waissengrin B, Agbarya A, Safadi E, et al. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet. Oncol. 2021;22:581-583. Go to original source... Go to PubMed...
    11. Nasti TH, Eberhardt CS. Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy. Vaccines. 2021;9:1396. https://doi.org/10.3390/ vaccines9121396. Go to original source... Go to PubMed...
    12. Smolej L, ©paček M, Pospíąilová ©, et al. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie (CLL) 2021[online]. Česká skupina pro chronickou lymfocytární leukémii 2021 [cit. 31-1-2022]. Dostupné z www.cll.cz.
    13. Chatzikonstantinou T, et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. 2021;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Go to original source... Go to PubMed...
    14. Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033-3040. doi:10.1182/blood.2020008150. Go to original source... Go to PubMed...
    15. Mandal A, Singh P, Samaddar A, et al. Vaccination of cancer patients against COVID-19: towards the end of a dilemma. Med Oncol. 2021;38(92). doi.org/10.1007/s12032-021-01540-8. Go to original source... Go to PubMed...
    16. První aktualizace doporučení České vakcinologické společnosti ČLS JEP (ČVS) k očkování proti onemocnění covid-19 27. srpna 2021 [online]. Česká vakcinologická společnost ČLS JEP 2021 [cit. 31-1-2022]. Dostupné z www.vakcinace.eu/doporuceni-a-stanoviska.
    17. McIntosh LJ, Bankier AA, Vijayaraghavan GR, et al. COVID-19 Vaccination-Related Uptake on FDG PET/CT: An emerging Dilemma and Suggestions for Management. American Journal of Roentgenology. 2021;217(4):975-979. Go to original source... Go to PubMed...
    18. Bitterman R, Eliakim-Raz N, Vinograd I, et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018;2(2):CD008983. doi:10.1002/14651858. Go to original source...
    19. El Ramahi R, Freifeld A. Epidemiology, Diagnosis, Treatment, and Prevention of Influenza Infection in Oncology Patients. Journal of Oncology Practice. 2019;15(4):177-184.doi: 10.1200/JOP.18.00567. Go to original source... Go to PubMed...
    20. Mariotti J, Spina F, Carniti C, et al. Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies. Eur J Haematol. 2012;89:111-119. doi.org/10.1111/j.1600-0609.2012.01793.x. Go to original source... Go to PubMed...
    21. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61(40):816-819. Go to PubMed...
    22. Doporučenî České vakcinologické společnosti ČLS JEP pro očkovánî proti pneumokokovým onemocněnîm v dospělosti 10. listopadu 2021 [online]. Česká vakcinologická společnost ČLS JEP 2021 [cit. 31-1-2022]. Dostupné z www.vakcinace.eu/doporuceni-a-stanoviska.
    23. Teepen JC, van Leeuwen FE, Tissing WJ, et al. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy. J Clin Oncol. 2017;35:2288-2298. Go to original source... Go to PubMed...
    24. Henderson TO, Fowler BW, Hamann HA, et al. Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factor. Cancer. 2022. https://doi.org/10.1002/cncr.33922. Go to original source... Go to PubMed...
    25. Kosina P, Haltmar J, Pellantová V, et al. Základní principy vakcinace dospělých pacientů po transplantaci hematopoetických buněk. Vakcinologie. 2019;13(2):57-61.
    26. Kosina P, et al. Doporučený postup péče o pacienty s poruąenou či zaniklou funkcí sleziny (hyposplenismem/asplenií) 2019. [online]. Aktualizace Doporučeného postupu Společnosti infekčního lékařství a České vakcinologické společnosti České lékařské společnosti J. E. Purkyně [cit. 31-1-2022]. Dostupné z www.infekce.cz/DopOPSI19.htm.
    27. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2000;19:16-923. Go to original source... Go to PubMed...
    28. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis. 2008;8:642-649. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.